Community-Acquired Pneumonia
Severity assessment drives every decision in CAP. CURB-65 and PSI/PORT determine level of care before you choose an antibiotic.
Definition and Recognition
Community-acquired pneumonia is an acute lower respiratory tract infection acquired outside of a hospital or healthcare facility. The diagnosis requires a new pulmonary infiltrate on chest imaging plus clinical signs of lower respiratory tract infection — fever, cough, sputum production, pleuritic chest pain, dyspnea, or abnormal lung exam findings. No single finding is sufficient; the diagnosis integrates the clinical picture with imaging.
Chest X-ray is the standard initial imaging study. CT chest is more sensitive and is appropriate when the diagnosis is uncertain, when the patient is not improving as expected, or when a complication such as empyema or lung abscess is suspected. A normal chest X-ray in a patient with clinical signs of pneumonia does not rule out early CAP — repeat imaging at 24–48 hours is appropriate in high-suspicion cases.
Typical vs. Atypical Presentations
Typical CAP — caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis — presents with abrupt onset of fever, productive cough, pleuritic chest pain, and lobar consolidation on imaging. Streptococcus pneumoniae remains the most common bacterial cause of CAP requiring hospitalization.
Atypical CAP — caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila — tends to present more gradually with dry cough, low-grade fever, and an interstitial or patchy infiltrate pattern. Mycoplasma is the most common atypical pathogen in younger outpatients and is often called 'walking pneumonia.' Legionella should be specifically considered in severe CAP, hyponatremia, diarrhea, recent travel, or immunocompromised patients.
The clinical distinction between typical and atypical CAP is unreliable. Empiric regimens for hospitalized patients must cover both categories — beta-lactam monotherapy is insufficient because it has no activity against atypical pathogens.
Initial Diagnostic Evaluation
Chest X-ray confirms the diagnosis and establishes a baseline for follow-up. Blood cultures before antibiotics are recommended in hospitalized patients, particularly those with severe CAP or suspected bacteremia. Sputum Gram stain and culture have low yield in most outpatient and non-ICU inpatient settings but are appropriate in severe CAP.
Urine Legionella antigen detects serogroup 1, which causes the majority of severe Legionella pneumonia. Send it in hospitalized patients with severe CAP, hyponatremia, diarrhea, recent travel, or immunocompromised status. Urine pneumococcal antigen is appropriate in ICU-level CAP.
Procalcitonin can help distinguish bacterial from viral lower respiratory tract infection but should not be used to withhold antibiotics when the clinical and radiographic picture is consistent with CAP. Its primary utility in CAP is guiding antibiotic de-escalation and duration — not the decision to start.
Severity Assessment and Disposition
Severity assessment is the first and most important step in CAP management — it determines the level of care before antibiotic selection. CURB-65 assigns one point each for: Confusion (new disorientation), Urea above 7 mmol/L (BUN above 19 mg/dL), Respiratory rate 30 or above, Blood pressure below 90 mmHg systolic or 60 mmHg diastolic, and age 65 or older. Score 0–1: outpatient treatment appropriate in most patients. Score 2: consider hospitalization. Score 3 or higher: hospitalization required; score 4–5 warrants consideration of ICU-level care.
PSI/PORT stratifies patients into five risk classes based on age, comorbidities, physical exam, and laboratory values. Risk classes I–II support outpatient treatment; class III may be treated outpatient or with brief hospitalization; classes IV–V require hospitalization. PSI/PORT is more discriminating at the low end of severity and identifies more patients who can safely be treated outpatient.
Both scoring systems inform clinical judgment — they do not replace it. A patient with a low CURB-65 score who has poor social support, inability to take oral medications, or significant comorbidities may still require hospitalization. Clinical gestalt and the ability to follow up reliably are part of the disposition decision.
Empiric Treatment Principles
Outpatient, no comorbidities: amoxicillin 1 g three times daily is the preferred agent for otherwise healthy patients. Doxycycline 100 mg twice daily is an alternative. Azithromycin monotherapy is no longer recommended as first-line in areas with macrolide resistance rates above 25%.
Outpatient, with comorbidities (chronic heart, lung, liver, or renal disease; diabetes; immunosuppression; antimicrobials in the past 3 months): combination therapy with amoxicillin-clavulanate or a cephalosporin plus a macrolide, or respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily).
Inpatient, non-ICU: beta-lactam (ampicillin-sulbactam, ceftriaxone, or cefotaxime) plus a macrolide, or respiratory fluoroquinolone monotherapy. The beta-lactam plus macrolide combination is preferred over fluoroquinolone monotherapy in most patients. Inpatient, ICU (severe CAP): beta-lactam plus azithromycin, or beta-lactam plus a respiratory fluoroquinolone. For Pseudomonas risk factors, use an anti-pseudomonal beta-lactam plus a fluoroquinolone or aminoglycoside plus azithromycin.
Treatment Duration, Reassessment, and Escalation
Standard treatment duration for CAP is 5 days for outpatient treatment and 5–7 days for hospitalized patients who are responding. Longer courses are appropriate for severe CAP, Legionella, bacteremic pneumonia, or patients with slow clinical response. Procalcitonin trending supports earlier discontinuation in patients who are improving.
Radiographic findings lag behind clinical improvement. Chest X-ray infiltrates can persist 4–6 weeks after clinical resolution. Persistent infiltrates at 48–72 hours are not treatment failure. True treatment failure is defined by clinical deterioration — worsening oxygenation, hemodynamic instability, or failure to defervesce — not by persistent imaging findings.
When CAP is not responding, broaden the differential: resistant organisms, atypical coverage gaps, empyema, lung abscess, non-infectious mimics (pulmonary edema, malignancy, organizing pneumonia), and immunocompromised states. Empyema requires drainage — antibiotics alone will not resolve it. Target SpO2 92–96% in most CAP patients; 88–92% in known COPD or chronic hypercapnia.
Want more depth?
Read the Deep Dive